Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TPX 0131

Next Previous
X
Search
Drug Profile

TPX 0131

Alternative Names: TPX-0131

Latest Information Update: 06 Jun 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Turning Point Therapeutics
  • Class Antineoplastics; Macrocyclic compounds; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 18 Apr 2023 Turning Point Therapeutics terminates a phase I/II FORGE-1 trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea, Australia, USA due to adverse change observed in the risk/benefit ratio (PO) (NCT04849273)
  • 17 Aug 2022 Turning Point Therapeutics has been acquired by Bristol-Myers Squibb
  • 02 Aug 2021 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (PO) (NCT04849273)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top